BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8568812)

  • 1. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y; Vogt A; Sebti SM; Hamilton AD
    J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.
    Hunt JT; Lee VG; Leftheris K; Seizinger B; Carboni J; Mabus J; Ricca C; Yan N; Manne V
    J Med Chem; 1996 Jan; 39(2):353-8. PubMed ID: 8558502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
    Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
    Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
    Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyl-derived inhibitors of ras farnesyl transferase.
    Kang MS; Stemerick DM; Zwolshen JH; Harry BS; Sunkara PS; Harrison BL
    Biochem Biophys Res Commun; 1995 Dec; 217(1):245-9. PubMed ID: 8526918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
    Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
    Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.
    James GL; Goldstein JL; Brown MS; Rawson TE; Somers TC; McDowell RS; Crowley CW; Lucas BK; Levinson AD; Marsters JC
    Science; 1993 Jun; 260(5116):1937-42. PubMed ID: 8316834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.
    Tolsma SS; Cohen JD; Ehrlich LS; Bouck NP
    Exp Cell Res; 1993 Apr; 205(2):232-9. PubMed ID: 8482334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of n-6 fatty acids on normal and v-Ki ras transformed NIH-3T3 cells.
    Cantrill RC; Ells GW; de Antueno RJ; Elliot M; Raha SK; Horrobin DF
    Anticancer Res; 1992; 12(6B):2197-201. PubMed ID: 1338278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between H-ras p21TLeu61 protein content and tumorigenicity of NIH3T3 cells.
    Bizub D; Blair D; Alvord G; Skalka AM
    Oncogene; 1988 Oct; 3(4):443-8. PubMed ID: 3078952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
    Qian Y; Blaskovich MA; Saleem M; Seong CM; Wathen SP; Hamilton AD; Sebti SM
    J Biol Chem; 1994 Apr; 269(17):12410-3. PubMed ID: 8175645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.